Grufity logoGrufity logo
StocksFundsSearch FilingsAPI

Seagen Inc. Stock Research

SGEN

206.39USD-0.60(-0.29%)Market Closed
Watchlist

Market Summary

USD206.39-0.60
Market Closed
-0.29%

SGEN Alerts

  • 6 major insider sales recently.
  • Big fall in earnings (Y/Y)
  • Losses in recent quarter

SGEN Stock Price

SGEN RSI Chart

SGEN Valuation

Market Cap

38.8B

Price/Earnings (Trailing)

-53.56

Price/Sales (Trailing)

17.97

EV/EBITDA

-58.18

Price/Free Cashflow

-53.72

SGEN Price/Sales (Trailing)

SGEN Profitability

EBT Margin

-31.00%

Return on Equity

-23.82%

Return on Assets

-18.3%

Free Cashflow Yield

-1.86%

SGEN Fundamentals

SGEN Revenue

Revenue (TTM)

2.2B

Revenue Y/Y

21.37%

Revenue Q/Q

16.18%

SGEN Earnings

Earnings (TTM)

-725.3M

Earnings Y/Y

-56.89%

Earnings Q/Q

-21.06%

Price Action

52 Week Range

210.50
(Low)(High)

Last 7 days

0.5%

Last 30 days

7.1%

Last 90 days

4.1%

Trailing 12 Months

45.8%

SGEN Financial Health

Current Ratio

3.65

SGEN Investor Care

Shares Dilution (1Y)

1.92%

Diluted EPS (TTM)

-3.88

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales

Latest Insider Trading transactions for SGEN

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2023-09-07
HIMES VAUGHN B
sold
-1,807,600
205
-8,785
chief technical officer
2023-09-07
HIMES VAUGHN B
acquired
387,331
44.09
8,785
chief technical officer
2023-08-31
LIU JEAN I
sold
-391,786
206
-1,893
chief legal officer
2023-08-31
DANSEY ROGER D
sold
-833,866
206
-4,029
president, r&d & cmo
2023-08-31
HIMES VAUGHN B
sold
-371,504
206
-1,795
chief technical officer
2023-08-31
ROMP CHARLES R
sold
-114,866
206
-555
evp, commercial u.s.
2023-08-31
SIMPSON TODD E
sold
-439,182
206
-2,122
chief financial officer
2023-08-29
HIMES VAUGHN B
sold
-76,426
206
-371
chief technical officer
2023-08-29
ROMP CHARLES R
sold
-90,228
206
-438
evp, commercial u.s.
2023-08-29
LIU JEAN I
sold
-83,430
206
-405
chief legal officer

1–10 of 50

Which funds bought or sold SGEN recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-09-12
Farther Finance Advisors, LLC
added
10.45
677
14,242
-%
2023-08-29
Garde Capital, Inc.
unchanged
-
-15,000
279,000
0.02%
2023-08-29
EFG Asset Management (Americas) Corp.
sold off
-100
-4,050,620
-
-%
2023-08-25
Yarbrough Capital, LLC
unchanged
-
-45,305
871,074
0.05%
2023-08-24
Alberta Investment Management Corp
added
520
3,372,510
4,060,910
0.04%
2023-08-23
CTC Alternative Strategies, Ltd.
new
-
371,063
371,063
0.46%
2023-08-22
COMERICA BANK
new
-
2,000
2,000
-%
2023-08-21
OSAIC HOLDINGS, INC.
reduced
-7.68
-1,361,900
9,660,940
0.02%
2023-08-21
BOKF, NA
sold off
-100
-810
-
-%
2023-08-21
Affinity Asset Advisors, LLC
sold off
-100
-4,049,400
-
-%

1–10 of 42

Latest Funds Activity

Are funds buying SGEN calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own SGEN
No. of Funds

Schedule 13G FIlings of Seagen

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Jun 09, 2023
capital international investors
3.9%
7,227,865
SC 13G/A
May 03, 2023
baker bros. advisors lp
23.8%
44,617,299
SC 13D/A
Mar 13, 2023
baker bros. advisors lp
25.1%
46,985,656
SC 13D/A
Feb 13, 2023
capital international investors
9.7%
18,058,081
SC 13G/A
Feb 09, 2023
vanguard group inc
6.97%
12,945,078
SC 13G/A
Feb 06, 2023
wellington management group llp
5.32%
9,881,292
SC 13G/A
Feb 01, 2023
blackrock inc.
6.4%
11,861,464
SC 13G/A
Mar 10, 2022
baker bros. advisors lp
25.6%
46,975,613
SC 13D/A
Feb 11, 2022
capital international investors
7.0%
12,778,429
SC 13G/A
Feb 04, 2022
wellington management group llp
6.36%
11,629,729
SC 13G

Recent SEC filings of Seagen

View All Filings
Date Filed Form Type Document
Sep 08, 2023
4
Insider Trading
Sep 07, 2023
144
Notice of Insider Sale Intent
Sep 05, 2023
8-K
Current Report
Sep 01, 2023
4
Insider Trading
Sep 01, 2023
4
Insider Trading
Sep 01, 2023
4
Insider Trading
Sep 01, 2023
4
Insider Trading
Sep 01, 2023
4
Insider Trading
Aug 31, 2023
144
Notice of Insider Sale Intent
Aug 31, 2023
144
Notice of Insider Sale Intent

Peers (Alternatives to Seagen)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
145.2B
26.6B
4.13% 21.09%
18.2
5.46
0.75% 21.34%
94.5B
27.4B
-0.16% 19.51%
17.24
3.45
-0.48% 32.56%
39.4B
10.7B
-6.80% -20.18%
32.68
3.7
-53.67% -91.41%
37.7B
10.0B
-1.71% 27.59%
14.15
3.78
-6.23% 29.40%
MID-CAP
11.2B
1.7B
5.59% 6.81%
63.29
6.67
29.01% 1345.90%
4.5B
-
-3.04% 140.92%
-7.66
48.33
54.84% -12.96%
3.1B
-
-4.51% -22.98%
-23.78
37.44
122.90% 54.78%
2.0B
80.2M
6.46% -52.82%
-6.01
24.54
42.17% -39.82%
SMALL-CAP
1.5B
121.2M
4.38% -25.42%
-5.13
12.17
-70.36% -531.73%
980.2M
15.3M
-15.63% 3.04%
-5.4
64.02
1090.59% -36.57%
664.9M
1.6B
-12.64% -74.33%
-1.13
0.42
23.74% 60.24%
221.7M
-
-17.58% -90.72%
-1.05
1.62
116.83% 16.61%
146.7M
-
-8.84% -84.12%
-0.74
0.61
113.96% -15.19%
112.7M
2.1M
-6.14% -67.90%
-1.12
54.83
487.70% -8.66%
4.1M
-
-12.28% -96.10%
-0.05
3.21
- -129.46%

Seagen News

Benzinga
(SGEN) - Analyzing Seagen's Short Interest - Seagen (NASDAQ:SGEN).
Benzinga,
30 hours ago
Zacks Investment Research
Investor's Business Daily

Returns for SGEN

Cumulative Returns on SGEN

16.2%


10-Year Cumulative Returns

20.5%


7-Year Cumulative Returns

21.6%


5-Year Cumulative Returns

4.6%


3-Year Cumulative Returns

Risks for SGEN

What is the probability of a big loss on SGEN?

71.2%


Probability that Seagen stock will be more than 20% underwater in next one year

60.8%


Probability that Seagen stock will be more than 30% underwater in next one year.

0%


Probability that Seagen stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does SGEN drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Seagen was unfortunately bought at previous high price.

Drawdowns

Financials for Seagen

Income Statement (Last 12 Months)
Income Statement (Last 12 Months)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Revenue5.2%2,162,001,0002,055,671,0001,962,412,0001,864,113,0001,777,873,0001,668,849,0001,574,371,0001,745,814,0002,383,485,0002,273,005,0002,175,536,0001,864,047,0001,015,579,000956,028,000916,713,000801,422,000757,583,000709,309,000654,700,000609,792,000575,659,000
Costs and Expenses7.1%2,914,044,0002,720,104,0002,575,382,0002,495,149,0002,514,067,0002,361,535,0002,256,427,0002,090,814,0001,792,336,0001,686,218,0001,578,684,0001,470,595,0001,350,097,0001,235,291,0001,137,258,0001,073,864,000985,815,000929,115,000914,698,000824,491,000776,981,000
  S&GA Expenses2.7%906,852,000883,179,000820,963,000815,799,000785,702,000730,573,000716,190,000663,618,000610,916,000571,428,000533,835,000490,699,000459,221,000415,910,000373,932,000338,170,000299,224,000275,185,000261,096,000230,079,000212,591,000
  R&D Expenses6.8%1,498,331,0001,402,717,0001,344,361,0001,290,812,0001,365,299,0001,295,906,0001,228,672,0001,140,563,000899,141,000862,357,000827,129,000812,007,000790,456,000756,308,000719,374,000668,085,000612,141,000571,072,000565,309,000526,041,000499,472,000
EBITDA100.0%--589,440,000-555,588,000-588,369,000-693,551,000-644,806,000-632,805,000-292,662,000638,329,000651,701,000651,701,0001,354,159,000-134,969,000-134,969,000-134,850,000------
EBITDA Margin100.0%--0.29-0.28-0.32-0.39-0.39-0.40-0.170.270.290.300.73-0.13-0.14-0.15------
Earnings Before Taxes-11.6%-711,105,000-637,188,000-602,315,000-635,461,000-739,669,000-689,525,000-675,705,000-332,847,000599,297,000911,830,667615,701,0001,330,478,000---158,650,000-367,652,000---246,346,000--
EBT Margin100.0%--0.31-0.31-0.34-0.42-0.41-0.43-0.190.250.270.280.71-0.16-0.17-0.17------
Net Income-11.8%-725,252,000-648,551,000-610,308,000-636,765,000-739,796,000-689,545,000-674,471,000-332,748,000597,266,000660,652,000613,670,000472,405,000-255,675,000-313,723,000-158,650,000-304,285,000-279,818,000-124,307,000-222,693,000-162,089,000-44,622,000
Net Income Margin100.0%--0.32-0.31-0.34-0.42-0.41-0.43-0.190.250.290.280.25-0.25-0.33-0.17------
Free Cashflow100.0%--585,180,000-531,091,000-719,364,000-651,907,000-652,705,000-551,337,000-81,745,000756,475,000735,633,000774,159,000570,684,000-312,408,000-259,044,000-234,490,000------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Assets-1.4%3,4953,5433,6753,6193,6303,6173,7203,9783,9523,9434,0013,0052,1652,0912,2062,0981,5681,5931,5031,5681,581
  Current Assets-3.3%2,5162,6022,8032,7602,7792,7712,8693,1153,0993,1043,0622,1661,3311,1601,1771,196672680654717706
    Cash Equivalents-8.2%30833632036337526142568541337455891911724927519364.0084.0078.00115159
  Inventory1.9%48747842736531927620118116314711697.0090.0085.0086.0092.0073.0067.0053.0075.0071.00
  Net PPE16.5%308264248230219214210209203197197193185175155145131115104101101
  Goodwill0%275275275275275275275275275275275275275275275275275275275251251
  Current Liabilities7.0%763713818726609531569698434390388593283257259246222208225194181
Shareholder's Equity-3.8%2,6192,7232,8042,8222,9332,9983,0653,1653,3913,4253,4882,2581,8141,7661,8761,7801,2721,3131,2741,3651,382
  Retained Earnings-9.1%-2,540-2,329-2,154-2,006-1,815-1,680-1,544-1,369-1,075-990-869-1,036-1,672-1,651-1,483-1,509-1,417-1,337-1,324-1,204-1,137
  Additional Paid-In Capital2.1%5,1555,0484,9544,8254,7474,6784,6084,5334,4664,4154,3573,2943,4853,4143,3593,2882,6882,6512,5982,5692,520
Shares Outstanding0.2%188187187185184184183182182181181174173172172168161161160159158
Cashflow (Last 12 Months)
(In Millions)
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Cashflow From Operations-21.3%-590-486-453-657-589-590-499-26.48814800857656-227-175-163-176-126-113-203-181-178
  Share Based Compensation16.2%28024122120919517917316115515214715514413512710598.0088.0079.0069.0064.00
Cashflow From Investing-9.2%394434228266469394289-1,035-1,343-1,519-1,419-30.29-371-292-277-359-38.70-59.18-592-556-566
Cashflow From Financing-0.9%12712912582.0086.0085.0078.0082982684484610165363363861370.0070.00713725707

SGEN Income Statement

2023-06-30
Condensed Consolidated Statements of Comprehensive Loss - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Revenues:    
Total revenues$ 603,832$ 497,502$ 1,123,551$ 923,962
Costs and expenses:    
Cost of sales180,753106,100292,529193,726
Research and development399,868304,254755,883601,913
Selling, general and administrative243,932220,259480,373394,484
Total costs and expenses824,553630,6131,528,7851,190,123
Loss from operations(220,721)(133,111)(405,234)(266,161)
Investment and other income (loss), net12,084(1,609)26,484(3,799)
Loss before income taxes(208,637)(134,720)(378,750)(269,960)
Provision for income taxes2,8911077,5151,361
Net loss$ (211,528)$ (134,827)$ (386,265)$ (271,321)
Net loss per share - basic (in dollars per share)$ (1.13)$ (0.73)$ (2.06)$ (1.48)
Net loss per share - diluted (in dollars per share)$ (1.13)$ (0.73)$ (2.06)$ (1.48)
Shares used in computation of per share amounts - basic (in shares)187,559184,145187,226183,897
Shares used in computation of per share amounts - diluted (in shares)187,559184,145187,226183,897
Comprehensive loss:    
Net loss$ (211,528)$ (134,827)$ (386,265)$ (271,321)
Other comprehensive income (loss):    
Unrealized gain (loss) on securities available-for-sale, net of tax172(2,736)1,542(3,597)
Foreign currency translation gain (loss)2282,819(944)2,925
Total other comprehensive income (loss)40083598(672)
Comprehensive loss(211,128)(134,744)(385,667)(271,993)
Net product sales    
Revenues:    
Total revenues543,974431,7141,012,613814,800
Royalty revenues    
Revenues:    
Total revenues51,18939,10981,36767,290
Collaboration and license agreement revenues    
Revenues:    
Total revenues$ 8,669$ 26,679$ 29,571$ 41,872

SGEN Balance Sheet

2023-06-30
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Jun. 30, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 308,441$ 319,940
Short-term investments983,6781,415,130
Accounts receivable, net586,048501,912
Inventories486,854427,211
Prepaid expenses and other current assets150,675138,340
Total current assets2,515,6962,802,533
Property and equipment, net307,518248,179
Operating lease right-of-use assets120,62846,738
Intangible assets, net226,072237,516
Goodwill274,671274,671
Other non-current assets50,79764,895
Total assets3,495,3823,674,532
Current liabilities:  
Accounts payable114,415207,851
Accrued liabilities and other648,483610,553
Total current liabilities762,898818,404
Long-term liabilities:  
Operating lease liabilities, long-term97,24243,474
Other long-term liabilities16,1838,835
Total long-term liabilities113,42552,309
Commitments and contingencies
Stockholders’ equity:  
Preferred stock, $0.001 par value, 5,000 shares authorized; none issued00
Common stock, $0.001 par value, 250,000 shares authorized; 187,672 shares issued and outstanding at June 30, 2023 and 186,559 shares issued and outstanding at December 31, 2022188187
Additional paid-in capital5,155,3754,954,469
Accumulated other comprehensive income4,1083,510
Accumulated deficit(2,540,612)(2,154,347)
Total stockholders’ equity2,619,0592,803,819
Total liabilities and stockholders’ equity$ 3,495,382$ 3,674,532
Roger D. Dansey
2680
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of advanced or metastatic urothelial cancer; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. It also develops TIVDAK for metastatic cervical cancer and other solid tumors; Ladiratuzumab Vedotin, an ADC targeting LIV-1 for metastatic breast cancer and solid tumors; Disitamab Vedotin, a novel HER2-targeted ADC; and SEA-CD40, SEA-TGT, SEA-BCMA, and SEA-CD70 for various cancer diseases. Seagen Inc. has collaboration agreements with Takeda Pharmaceutical Company Limited; Agensys, Inc.; Genmab A/S; Merck; and RemeGen, Co. Ltd. The company was formerly known as Seattle Genetics, Inc. and changed its name to Seagen Inc. in October 2020. Seagen Inc. was incorporated in 1997 and is headquartered in Bothell, Washington.